Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

33.89
-0.4700-1.37%
Post-market: 33.920.0300+0.09%19:59 EDT
Volume:1.50M
Turnover:51.30M
Market Cap:3.95B
PE:-7.26
High:34.98
Open:34.79
Low:33.47
Close:34.36
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:0.91
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:9.68
PE(LYR):-10.62

Loading ...

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist Vk3019 in Healthy Adults

THOMSON REUTERS
·
Jun 24

Viking Therapeutics - to Initiate Phase 3 Trial of Oral Vk2735 Later This Year

THOMSON REUTERS
·
Jun 24

Viking Therapeutics - Expects to Report Vk2735 Dosing Study Results in 3Q26

THOMSON REUTERS
·
Jun 24

Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735

Simply Wall St.
·
Jun 20

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Jun 18

Viking Therapeutics management to meet with B. Riley

TIPRANKS
·
Jun 16

Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)?

Simply Wall St.
·
Jun 14

Viking Therapeutics appoints Hubert Chen as chief medical officer

Reuters
·
Jun 11

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.d., as Chief Medical Officer

THOMSON REUTERS
·
Jun 11

Viking Therapeutics files Form 3 for Chief Medical Officer Hubert C. Chen

Reuters
·
Jun 04

Analyst Reiterates Buy on Viking Therapeutics, Citing Best-in-Class Obesity Pipeline and Multiple Value-Creation Catalysts

TIPRANKS
·
Jun 03

Viking Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
May 29

Lake Street Initiates Viking Therapeutics With Buy Rating, $89 Price Target

MT Newswires Live
·
May 28

Viking Therapeutics (VKTX) Initiated with a Buy at Truist Financial

TIPRANKS
·
May 27

Viking Therapeutics shareholders elect Singleton, Rouan as Class II directors

Reuters
·
May 27

Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings?

Simply Wall St.
·
May 26

Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors?

Simply Wall St.
·
May 23

Viking Therapeutics to present at William Blair Growth Stock Conference

Reuters
·
May 21

How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story

Simply Wall St.
·
May 15

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

TIPRANKS
·
May 12